Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1980 Oct;35(10):781–787. doi: 10.1136/thx.35.10.781

Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma.

H M Jansen, T H The, N G Orie
PMCID: PMC471380  PMID: 7466726

Abstract

Fifty-four patients with evidence of locally advanced primary squamous cell bronchial carcinoma (SCC), and three patients with adenocarcinoma (AC) had lung resection to remove all the visible tumour. After operation an randomly chosen group of 20 SCC patients received adjuvant BCG immunostimulation by scarifications (BCG-A). An additional group of 14 SCC patients, and three AC patients received initially intrapleural BCG treatment and subsequently scarifications (BCG-B). A control group of 20 SCC patients received no adjuvant treatment. Follow-up studies were done from three to 51 months. Immune reactivity was monitored in vivo with PPD skin tests in 33 treated and in 18 untreated patients. In both the BCG-treated SCC groups recurrence rates decreased statistically significant during follow-up (BCG-A; six to 51 months, p less than 0.001; BCG: 6-9 months, p less than 0.01 and nine to 24 months, p less than 0.001). However, no difference could be demonstrated between systemic and combined systemic and intrapleural treatment. The three BCG-treated AC patients all relapsed within nine months of follow-up. A pronounced increase in skin reactivity to PPD was seen six months after surgery in the BCG-treated patients (BCG-A, p less than 0.001; BCG-B, p less than 0.01), whereas the control patients remained anergic after surgery. This improved immune reactivity went in parallel with a more favourable outcome of the individual patients (BCG-A, p less than 0.02; BCG-B, p less than 0.05). It is concluded that adjuvant BCG immunotherapy used in strongly selected patients with minimal residual squamous cell bronchial carcinoma improves the prognosis. Intrapleural treatment did not improve the prognosis further. A favourable clinical outcome was mirrored by an increase in cellular immune reactivity.

Full text

PDF
781

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer (first of two parts). N Engl J Med. 1974 Jun 20;290(25):1413–1420. doi: 10.1056/NEJM197406202902506. [DOI] [PubMed] [Google Scholar]
  2. Broder L. E., Cohen M. H., Selawry O. S. Treatment of bronchogenic carcinoma. II. Small cell. Cancer Treat Rev. 1977 Dec;4(4):219–260. doi: 10.1016/s0305-7372(77)80001-7. [DOI] [PubMed] [Google Scholar]
  3. Evans D. A. Immunology of bronchial carcinoma. Thorax. 1976 Oct;31(5):493–506. doi: 10.1136/thx.31.5.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. GEHAN E. A. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika. 1965 Jun;52:203–223. [PubMed] [Google Scholar]
  5. Homan van der Heide J. N., Stam H. C., Van der Wal A. M. The results of a combined attack on bronchial carcinoma by radiotherapy and surgery. Bronches. 1974 Mar-Apr;24(2):70–78. [PubMed] [Google Scholar]
  6. Hortobagyi G. N., Richman S. P., Dandridge K., Gutterman J. U., Blumenschein G. R., Hersh E. M. Immunotherapy with BCG administered by scarification: standardization of reactions and management of side effects. Cancer. 1978 Nov;42(5):2293–2303. doi: 10.1002/1097-0142(197811)42:5<2293::aid-cncr2820420529>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  7. Ioachim H. L., Dorsett B. H., Paluch E. The immune response at the tumor site in lung carcinoma. Cancer. 1976 Dec;38(6):2296–2309. doi: 10.1002/1097-0142(197612)38:6<2296::aid-cncr2820380617>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  8. Jansen H. M., Esselink M. T., Orie N. G., The T. H. Cell-mediated immune response in patients with bronchial carcinoma. Relation between clinical parameters and various immunological tests for immune status investigation. Neth J Med. 1979;22(1):1–9. [PubMed] [Google Scholar]
  9. Jansen H. M., The T. H., de Gast G. C., Esselink M. T., van der Wal A. M., Orie N. G. Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial). Thorax. 1978 Aug;33(4):429–438. doi: 10.1136/thx.33.4.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. McKneally M. F., Maver C. M., Kausel H. W. Intrapleural B.C.G. immunostimulation in lung cancer. Lancet. 1977 Mar 12;1(8011):593–593. doi: 10.1016/s0140-6736(77)92015-3. [DOI] [PubMed] [Google Scholar]
  11. McKneally M. F., Maver C., Kausel H. W. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet. 1976 Feb 21;1(7956):377–379. doi: 10.1016/s0140-6736(76)90212-9. [DOI] [PubMed] [Google Scholar]
  12. Morton D. L., Goodnight J. E., Jr Clinical trials of immunotherapy: present status. Cancer. 1978 Nov;42(5):2224–2233. doi: 10.1002/1097-0142(197811)42:5<2224::aid-cncr2820420521>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  13. Petrovich Z., Ohanian M., Cox J. Clinical research on the treatment of locally advanced lung cancer: final report of VALG Protocol 13 Limited. Cancer. 1978 Sep;42(3):1129–1134. doi: 10.1002/1097-0142(197809)42:3<1129::aid-cncr2820420315>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  14. Ritch P. S., McCredie K. B., Gutterman J. U., Hersh E. M. Disseminated BCG disease associated with immunotherapy by scarification in acute leukemia. Cancer. 1978 Jul;42(1):167–170. doi: 10.1002/1097-0142(197807)42:1<167::aid-cncr2820420128>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  15. Sparks F. C. Hazards and complications of BCG immunotherapy. Med Clin North Am. 1976 May;60(3):499–509. doi: 10.1016/s0025-7125(16)31894-6. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES